COMMUNIQUÉS West-GlobeNewswire

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

11/12/2017 - 14:00

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 11, [...]

Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors

11/12/2017 - 14:00

SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small molecule Wnt pathway inhibitor in oral tablet formulation. This [...]

Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

11/12/2017 - 14:00

Eight of 12 patients (67 percent) with cardiac involvement responded to therapy with a median time to cardiac response of 21 days 14 of 24 (63 percent) of patients demonstrated organ response CAEL-101 dosed once weekly [...]

Vital Therapies Added to NASDAQ Biotechnology Index

11/12/2017 - 14:00

SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL ), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced [...]

Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

11/12/2017 - 13:45

PHILADELPHIA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that it has [...]

Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting

11/12/2017 - 13:31

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for [...]

Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland

11/12/2017 - 13:30

ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the first [...]

Mucodel Pharma LLC Announces Successful Completion of Clinical Study of its Co-Gel Intranasal Naloxone Formulation

11/12/2017 - 13:30

Greensboro, NC, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving intranasal naloxone, a Mucodel product under development for [...]

SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox

11/12/2017 - 13:30

– Company requests Priority Review of TPOXX NDA – – If approved, would be the first treatment for deadly smallpox – NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health [...]

Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysis

11/12/2017 - 13:30

Study Presented at the 59 th American Society of Hematology (ASH) Annual Meeting Study focused on DLBCL (Diffuse Large B-Cell Lymphomas) RUTHERFORD, N.J., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq [...]

Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma

11/12/2017 - 13:30

IRVING, Texas, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA ) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the presentation of interim data from [...]

Insider tradings

11/12/2017 - 11:26

Please see enclosed pdf.

Proposal of candidates to the Board of Directors

11/12/2017 - 11:07

The election of board members will be held at the Annual Shareholders’ Meeting on March 13, 2018, and the Board of Directors is today proposing candidates for that one-year term election. The Board of Directors is [...]

REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED

11/12/2017 - 10:51

Copenhagen, 2017-12-11 10:51 CET (GLOBE NEWSWIRE) -- This release does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, [...]

Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting

11/12/2017 - 08:01

Company announcement, Helsinki, 11 December 2017, at 9.00 AM Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting Nexstim Plc (NXTMH:HEX [...]

Galapagos to enter NASDAQ Biotech Index

11/12/2017 - 07:31

Mechelen, Belgium; 11 December 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces that it will be included in NASDAQ Biotech Index on NASDAQ, effective 18 December 2017. The NASDAQ Biotech Index (NBI [...]

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

11/12/2017 - 07:06

Workshop to be held on Monday, December 11 th at 12:00 pm EST December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

11/12/2017 - 07:01

Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the [...]

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

11/12/2017 - 07:01

Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study 75% of ARGX-113 treated patients had a [...]